B+
Bull case
30%
Probability
Target price
$171.00
Analysis reference price unavailable
Analysis 2026-10-30 · RankAlpha Sentiment Codex
MRK
MerckANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$158.64
Analysis reference price unavailable
Analysis 2026-10-30 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$125.00
Analysis reference price unavailable
Analysis 2026-10-30 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-30
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+62.9
Score
AI commentary
Initial post-print tone is positive: packet coverage reported shares up more than 5% after the raised outlook, but a verified closing reaction is unavailable. Two reported target increases are modest, and the cited Guggenheim report notes purchase-timing benefit. Social, options, short-interest and employee measures were not supplied; the zero fields above mean unavailable, not neutral observations. The anchor is the October 29 adjusted close, not a verified October 30 price.
RankAlpha Sentiment Codex - 2026-10-30
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-11-06catalystQ3 beat and raised 2026 outlookMedium impact
Merck reported $18.085 billion of Q3 sales and $2.49 non-GAAP EPS, versus $17.276 billion and $2.58 a year earlier, and raised the midpoint of its 2026 sales range to $66.8–$67.3 billion. The $2.77–$2.82 EPS outlook includes a $0.12 SciBrunch licensing charge. Zacks reported $2.12 EPS consensus; the beat should be weighed against reported purchase-timing benefits rather than extrapolated fully. [#SEC-8K-2026-10-29] Zacks Guggenheim coverage
2027-06-30eventSac-TMT regulatory progressMedium impact
Merck reported pivotal TroFuse-005 data in endometrial cancer and FDA acceptance of a priority-review biologics application. The program is licensed from Kelun-Biotech; approval, label breadth and commercialization remain uncertain. No FDA decision date is established in the packet. [#SEC-8K-2026-10-29] [#REL-8733dda2-b695-4d4f-ab51-177253b4bc1c]
2027-06-30catalystNew-product uptake versus portfolio costsMedium impact
Q3 KEYTRUDA/KEYTRUDA QLEX sales were $8.6 billion, including $830 million of QLEX, while WINREVAIR reached $694 million. Sustained uptake could support portfolio diversification, but launch investment and exclusivity losses may temper 2027 growth. Merck also announced a global SciBrunch license for preclinical MK-2690; its undisclosed economics and early stage preclude a near-term revenue assumption. [#SEC-8K-2026-10-29] [#REL-3ca5d58f-4ffd-471d-aca0-d3578393896f]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-30 • Updated nightlySource: Internal modelMethodology